Modality
siRNA
MOA
WRNi
Target
WRN
Pathway
DDR
Breast Ca
Development Pipeline
Preclinical
~Jun 2010
→ ~Sep 2011
Phase 1
~Dec 2011
→ ~Mar 2013
Phase 2
~Jun 2013
→ ~Sep 2014
Phase 3
~Dec 2014
→ ~Mar 2016
NDA/BLA
~Jun 2016
→ ~Sep 2017
Approved
Dec 2017
→ Jun 2028
ApprovedCurrent
NCT05404056
1,982 pts·Breast Ca
2024-02→2028-05·Terminated
NCT04380873
1,293 pts·Breast Ca
2017-12→2028-06·Completed
3,275 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2026-07-254mo awayConference· Breast Ca
2028-05-092.1y awayPh3 Readout· Breast Ca
2028-06-222.2y awayPh3 Readout· Breast Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Approved
Complet…
Approved
Termina…
Catalysts
Conference
2026-07-25 · 4mo away
Breast Ca
Ph3 Readout
2028-05-09 · 2.1y away
Breast Ca
Ph3 Readout
2028-06-22 · 2.2y away
Breast Ca
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05404056 | Approved | Breast Ca | Terminated | 1982 | VA |
| NCT04380873 | Approved | Breast Ca | Completed | 1293 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 |